PDF(Pubmed)
Abstract：
The increasing utilization of Glucagon-like Peptide-1 receptor agonists (GLP-1 RAs) in managing type 2 diabetes mellitus has raised interest regarding their impact on thyroid function. In fact, while these agents are well known for their efficacy in glycemic control and weight management, their association with thyroid disorders requires clarification due to the complex interplay between thyroid hormones and metabolic pathways. Thyroid dysfunction commonly co-occurs with metabolic conditions such as diabetes and obesity, suggesting a profound interconnection between these systems. This review aims to contribute to a deeper understanding of the interaction between GLP-1 RAs and thyroid dysfunction and to clarify the safety of GLP-1 RAs in diabetic patients with thyroid disorders. By synthesizing existing evidence, this review highlights that, despite various studies exploring this topic, current evidence is inconclusive, with conflicting results. It is important to note that these drugs are relatively recent, and longer-term studies with larger sample sizes are likely needed to draw clearer conclusions. Currently, no existing guidelines provide definitive directions on this clinical issue; however, it is advisable to include thyroid function tests in the routine screening of diabetic patients, particularly those treated with GLP-1 Ras, with the goal of optimizing patient care and management.
摘要：
胰高血糖素样肽-1受体激动剂（GLP-1RA）在治疗2型糖尿病中的应用日益增加，这引起了人们对其对甲状腺功能影响的兴趣。事实上,虽然这些药物在血糖控制和体重管理方面的功效是众所周知的，由于甲状腺激素和代谢途径之间复杂的相互作用,它们与甲状腺疾病的关联需要澄清.甲状腺功能障碍通常与糖尿病和肥胖等代谢疾病同时发生，暗示了这些系统之间的深刻联系。本文旨在深入了解GLP-1RA与甲状腺功能异常之间的相互作用，并阐明GLP-1RA在糖尿病合并甲状腺疾病患者中的安全性。通过综合现有证据，这篇评论强调，尽管有各种研究探索了这个话题，目前证据不足,结果相互矛盾。重要的是要注意，这些药物是相对较新的，和更大样本量的长期研究可能需要得出更清晰的结论。目前,现有的指南没有提供关于这一临床问题的明确指导；然而，建议在糖尿病患者的常规筛查中包括甲状腺功能检查，特别是那些用GLP-1Ras治疗的患者，以优化患者护理和管理为目标。
